Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Breast Cancer
Primary Peritoneal Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Natural killer cells
Drug: IL-2
Drug: Interleukin-2
Drug: Methylprednisolone

First Posted Date: 2010-04-16

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 13

Registration Number: NCT01105650

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Myelodysplastic Syndromes
Recurrent Childhood Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

Interventions: Procedure: double-unit umbilical cord blood transplantation
Other: cytogenetic analysis
Procedure: bone marrow aspiration
Other: fluorescence in situ hybridization
Drug: busulfan
Drug: cyclophosphamide
Drug: anti-thymocyte globulin
Drug: methylprednisolone
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: flow cytometry
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2010-03-26

Last Posted Date: 2019-01-23

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT01093586

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Phase 2

Completed

Conditions: Systemic Sclerosis-Associated PAH

Interventions: Biological: Rituximab
Other: Placebo
Diagnostic Test: CMRI
Drug: prednisone
Drug: methylprednisolone
Drug: diphenhydramine
Drug: acetaminophen

First Posted Date: 2010-03-15

Last Posted Date: 2023-02-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT01086540

Locations: 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸
University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

and more 14 locations

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate Mofetil
Drug: Laquinimod
Drug: Prednisolone/Prednisone
Drug: Placebo
Drug: Methylprednisolone

First Posted Date: 2010-03-11

Last Posted Date: 2022-03-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 46

Registration Number: NCT01085097

Locations: 🇺🇸
Teva Investigational Site 1022, Lake Success, New York, United States
🇬🇧
Teva Investigational Site 3412, Dudley, United Kingdom
🇨🇦
Teva Investigational Site 1114, Winnipeg, Manitoba, Canada

and more 27 locations

Treatment Interruption of Natalizumab

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: natalizumab
Other: IV placebo
Drug: interferon beta 1-a
Drug: methylprednisolone
Drug: glatiramer acetate

First Posted Date: 2010-02-19

Last Posted Date: 2013-09-19

Lead Sponsor: Biogen

Target Recruit Count: 175

Registration Number: NCT01071083

Locations: 🇪🇸
Research Site, Valencia, Spain

Pulse ACTH vs. MP for MS

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: ACTH
Drug: Methylprednisolone

First Posted Date: 2010-01-14

Last Posted Date: 2017-04-19

Lead Sponsor: University of Southern California

Target Recruit Count: 23

Registration Number: NCT01049451

Locations: 🇺🇸
USC MS Center, Los Angeles, California, United States

Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord

Phase 1

Completed

Conditions: Spinal Cord Injuries

Interventions: Biological: Umbilical Cord Blood Mononuclear Cell
Drug: Methylprednisolone
Drug: Lithium

First Posted Date: 2010-01-12

Last Posted Date: 2014-01-28

Lead Sponsor: China Spinal Cord Injury Network

Target Recruit Count: 8

Registration Number: NCT01046786

Locations: 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Phase 2

Terminated

Conditions: Clinically Isolated Syndrome
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

Interventions: Drug: PEG-liposomal prednisolone sodium phosphate
Drug: Methylprednisolone

First Posted Date: 2009-12-24

Last Posted Date: 2016-10-06

Lead Sponsor: Galapagos NV

Target Recruit Count: 15

Registration Number: NCT01039103

Locations: 🇵🇱
Diagnomed-Clinical Research Sp. z o.o., Katowice, Poland
🇩🇪
St. Josef Hospital der Ruhr, Bochum, Germany
🇩🇪
Klinikum Rechts der Isar der technischen Universitaet Muenchen, Neurologische Klinik und Poliklinik, Muenchen, Germany

and more 5 locations